@Pharmdca Q2 (&amp; Q3) ERs are impacted(?),
This, along w Covid resurgence likely to bring back -1k-2k mkt down days(?)
Going to cash for Aug (&amp; Oct) ERs as possible,
Keeping mostly biotechs: ie. $CBIO  $CLVS  $SGMO $MRK $KPTI ...